MASSARI, Francesco Saverio
 Distribuzione geografica
Continente #
NA - Nord America 244
EU - Europa 108
Continente sconosciuto - Info sul continente non disponibili 24
AS - Asia 3
SA - Sud America 1
Totale 380
Nazione #
US - Stati Uniti d'America 204
IT - Italia 91
CA - Canada 20
GB - Regno Unito 10
CR - Costa Rica 5
GP - Guadalupe 4
BD - Bangladesh 2
CW - ???statistics.table.value.countryCode.CW??? 2
EE - Estonia 2
IE - Irlanda 2
JM - Giamaica 2
PR - Porto Rico 2
TT - Trinidad e Tobago 2
BR - Brasile 1
BS - Bahamas 1
CN - Cina 1
DE - Germania 1
FR - Francia 1
HN - Honduras 1
LC - Santa Lucia 1
RU - Federazione Russa 1
SV - El Salvador 1
VC - Saint Vincent e Grenadine 1
Totale 358
Città #
Council Bluffs 35
Ashburn 34
Milan 18
North Bergen 17
Santa Clara 16
Naples 9
Rome 8
San Jose 5
Los Angeles 4
Miano 4
San José 4
Dallas 3
Genoa 3
New York 3
Philadelphia 3
Tampa 3
Brescia 2
Casier 2
Richmond 2
Seveso 2
Turin 2
Afragola 1
Albany 1
Atlanta 1
Barataria 1
Bari 1
Barrie 1
Basiglio 1
Beijing 1
Bellante Stazione 1
Boise 1
Capesterre-Belle-Eau 1
Carolina 1
Castries 1
Catania 1
Chaguanas 1
Chalmette 1
Charlottetown 1
Cicognolo 1
Columbus 1
Concesio 1
East Orange 1
Edmonton 1
Florence 1
Frankfurt am Main 1
Grimaldi 1
Heredia 1
Huntington Beach 1
Jacksonville 1
Juazeiro 1
Katonah 1
Kingsport 1
Kingston 1
Kingstown 1
Les Abymes 1
Lexington 1
London 1
Longueuil 1
Marietta 1
Menifee 1
Minneapolis 1
Mississauga 1
Moncton 1
Montego Bay 1
Montesilvano 1
Montoro 1
Montreal 1
Monza 1
Muncie 1
Murrieta 1
Nanterre 1
Nassau 1
Nepean 1
New Haven 1
North Hollywood 1
North York 1
Norwalk 1
Phoenix 1
Pittsburgh 1
Queens 1
Reggio Emilia 1
Regina 1
Richmond Hill 1
Rimini 1
Rochester 1
Roseville 1
Saint-Hubert 1
Sainte-Rose 1
San Cesareo 1
San Juan 1
San Salvador 1
Scarborough 1
Seattle 1
Somerset 1
Spoltore 1
Stoney Creek 1
Tallahassee 1
Tegucigalpa 1
The Bronx 1
Toronto 1
Totale 258
Nome #
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors 29
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1) 25
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 24
Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma 23
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study 20
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial 19
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study 19
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care 18
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 18
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study 18
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? 17
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations 17
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis 16
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison 16
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies 15
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases 15
Impact of Influenza Syndrome and Flu Vaccine on Survival of Cancer Patients During Immunotherapy in the INVIDIa Study 14
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib 14
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study 13
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 12
Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy 9
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors 9
Totale 380
Categoria #
all - tutte 1.414
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.414


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2025/20263 0 0 0 0 0 0 0 0 0 0 3 0
2026/2027377 17 35 79 215 31 0 0 0 0 0 0 0
Totale 380